The EU had previously approved two vaccines for protecting ... "This approval of the first mRNA vaccine against RSV clearly shows the importance of innovation when it comes to protecting the ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial ...

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

The EU follows the US in approving the use of the shot in the younger age range in people with conditions like chronic ...

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

London open The FTSE 100 is expected to open 10 points higher on Thursday, having closed down 0.02% on Wednesday at 8,343.85.

(Family Features) Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One ...

In adults 60 and over, vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

RSV is a highly contagious seasonal virus that can cause severe symptoms in infants and the elderly -- one in 20 of whom ...